Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NabucCO
- 02 Feb 2017 Status changed from recruiting to completed.
- 11 Oct 2016 Results of Phase I portion (n=63) of study presented at the 41st European Society for Medical Oncology Congress.
- 15 May 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jul 2015 to 1 Dec 2015.